TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

Joseph A. Sparano, Lori J. Goldstein, Nancy E. Davidson, George W. Sledge, Robert Gray

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The purpose of this study is to evaluate the relationship between TOP2A RNA expression and recurrence in patients with operable estrogen receptor (ER)-positive breast cancer. We evaluated TOP2A expression in a pooled analysis of four independent datasets with gene expression data including 752 patients with early stage, ER-positive, HER2-negative breast cancer, most of whom received either no adjuvant therapy or only endocrine therapy without chemotherapy. We also used an algorithm to simulate the Oncotype DX Recurrence Score (simRS) and the proliferation component of the Recurrence Score (simPS). Results are expressed as the hazard ratio (HR) for estimates of the effect of a 1SD increase in the value of the log gene expression (x + 1SD vs. x) as a continuous function. TOP2A expression was significantly associated with recurrence (HR 1.56, p <0.0001), and after adjustment for simRS (HR 1.26, p = 0.003). TOP2A correlated somewhat with simRS (0.45), but more strongly with simPS (0.69). For those with an intermediate simRS, high TOP2A expression (above the median) was associated with significantly higher relapse rates at 5 years (HR 1.82, p = 0.007). TOP2A expression provides prognostic information in patients with ER-positive, HER2-negative breast cancer, a population known to have low incidence of TOP2A gene alterations. These findings confirm prior reports indicating that TOP2A expression provides prognostic information in ER-positive breast cancer. TOP2A expression may also be useful for identifying those with an intermediate RS who are more likely to relapse, although additional validation in datasets including measured rather than simulated RS will be required.

Original languageEnglish (US)
Pages (from-to)751-757
Number of pages7
JournalBreast Cancer Research and Treatment
Volume134
Issue number2
DOIs
StatePublished - Jul 2012

Fingerprint

Estrogen Receptors
RNA
Breast Neoplasms
Recurrence
Gene Expression
Drug Therapy
Incidence
Therapeutics
Population
Genes
Datasets

Keywords

  • Breast cancer
  • Recurrence
  • TOP2A RNA expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. / Sparano, Joseph A.; Goldstein, Lori J.; Davidson, Nancy E.; Sledge, George W.; Gray, Robert.

In: Breast Cancer Research and Treatment, Vol. 134, No. 2, 07.2012, p. 751-757.

Research output: Contribution to journalArticle

Sparano, Joseph A. ; Goldstein, Lori J. ; Davidson, Nancy E. ; Sledge, George W. ; Gray, Robert. / TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. In: Breast Cancer Research and Treatment. 2012 ; Vol. 134, No. 2. pp. 751-757.
@article{4c7273f020124a959d70478695aa18d3,
title = "TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer",
abstract = "The purpose of this study is to evaluate the relationship between TOP2A RNA expression and recurrence in patients with operable estrogen receptor (ER)-positive breast cancer. We evaluated TOP2A expression in a pooled analysis of four independent datasets with gene expression data including 752 patients with early stage, ER-positive, HER2-negative breast cancer, most of whom received either no adjuvant therapy or only endocrine therapy without chemotherapy. We also used an algorithm to simulate the Oncotype DX Recurrence Score (simRS) and the proliferation component of the Recurrence Score (simPS). Results are expressed as the hazard ratio (HR) for estimates of the effect of a 1SD increase in the value of the log gene expression (x + 1SD vs. x) as a continuous function. TOP2A expression was significantly associated with recurrence (HR 1.56, p <0.0001), and after adjustment for simRS (HR 1.26, p = 0.003). TOP2A correlated somewhat with simRS (0.45), but more strongly with simPS (0.69). For those with an intermediate simRS, high TOP2A expression (above the median) was associated with significantly higher relapse rates at 5 years (HR 1.82, p = 0.007). TOP2A expression provides prognostic information in patients with ER-positive, HER2-negative breast cancer, a population known to have low incidence of TOP2A gene alterations. These findings confirm prior reports indicating that TOP2A expression provides prognostic information in ER-positive breast cancer. TOP2A expression may also be useful for identifying those with an intermediate RS who are more likely to relapse, although additional validation in datasets including measured rather than simulated RS will be required.",
keywords = "Breast cancer, Recurrence, TOP2A RNA expression",
author = "Sparano, {Joseph A.} and Goldstein, {Lori J.} and Davidson, {Nancy E.} and Sledge, {George W.} and Robert Gray",
year = "2012",
month = "7",
doi = "10.1007/s10549-012-2112-7",
language = "English (US)",
volume = "134",
pages = "751--757",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer

AU - Sparano, Joseph A.

AU - Goldstein, Lori J.

AU - Davidson, Nancy E.

AU - Sledge, George W.

AU - Gray, Robert

PY - 2012/7

Y1 - 2012/7

N2 - The purpose of this study is to evaluate the relationship between TOP2A RNA expression and recurrence in patients with operable estrogen receptor (ER)-positive breast cancer. We evaluated TOP2A expression in a pooled analysis of four independent datasets with gene expression data including 752 patients with early stage, ER-positive, HER2-negative breast cancer, most of whom received either no adjuvant therapy or only endocrine therapy without chemotherapy. We also used an algorithm to simulate the Oncotype DX Recurrence Score (simRS) and the proliferation component of the Recurrence Score (simPS). Results are expressed as the hazard ratio (HR) for estimates of the effect of a 1SD increase in the value of the log gene expression (x + 1SD vs. x) as a continuous function. TOP2A expression was significantly associated with recurrence (HR 1.56, p <0.0001), and after adjustment for simRS (HR 1.26, p = 0.003). TOP2A correlated somewhat with simRS (0.45), but more strongly with simPS (0.69). For those with an intermediate simRS, high TOP2A expression (above the median) was associated with significantly higher relapse rates at 5 years (HR 1.82, p = 0.007). TOP2A expression provides prognostic information in patients with ER-positive, HER2-negative breast cancer, a population known to have low incidence of TOP2A gene alterations. These findings confirm prior reports indicating that TOP2A expression provides prognostic information in ER-positive breast cancer. TOP2A expression may also be useful for identifying those with an intermediate RS who are more likely to relapse, although additional validation in datasets including measured rather than simulated RS will be required.

AB - The purpose of this study is to evaluate the relationship between TOP2A RNA expression and recurrence in patients with operable estrogen receptor (ER)-positive breast cancer. We evaluated TOP2A expression in a pooled analysis of four independent datasets with gene expression data including 752 patients with early stage, ER-positive, HER2-negative breast cancer, most of whom received either no adjuvant therapy or only endocrine therapy without chemotherapy. We also used an algorithm to simulate the Oncotype DX Recurrence Score (simRS) and the proliferation component of the Recurrence Score (simPS). Results are expressed as the hazard ratio (HR) for estimates of the effect of a 1SD increase in the value of the log gene expression (x + 1SD vs. x) as a continuous function. TOP2A expression was significantly associated with recurrence (HR 1.56, p <0.0001), and after adjustment for simRS (HR 1.26, p = 0.003). TOP2A correlated somewhat with simRS (0.45), but more strongly with simPS (0.69). For those with an intermediate simRS, high TOP2A expression (above the median) was associated with significantly higher relapse rates at 5 years (HR 1.82, p = 0.007). TOP2A expression provides prognostic information in patients with ER-positive, HER2-negative breast cancer, a population known to have low incidence of TOP2A gene alterations. These findings confirm prior reports indicating that TOP2A expression provides prognostic information in ER-positive breast cancer. TOP2A expression may also be useful for identifying those with an intermediate RS who are more likely to relapse, although additional validation in datasets including measured rather than simulated RS will be required.

KW - Breast cancer

KW - Recurrence

KW - TOP2A RNA expression

UR - http://www.scopus.com/inward/record.url?scp=84868193105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868193105&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2112-7

DO - 10.1007/s10549-012-2112-7

M3 - Article

C2 - 22706628

AN - SCOPUS:84868193105

VL - 134

SP - 751

EP - 757

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -